Retrieved June 11, 2025, from Swiss Medica
Although this initial case only involves the drug manufacturers as defendants, it is anticipated that more claims and lawsuits targeting not only Ozempic, but also other GLP-1 drugs, will emerge
The current meta-analysis confirms that tirzepatide is not associated with an increased overall cancer risk
A retrospective study of amitriptyline in youth with autism spectrum disorders
This also shifted GLP-1 therapy from being purely a metabolic medication to a cardiovascular diseasemodifying therapy, even in patients without diabetes
Non-GLP therapies may be considered for patients who: Are not candidates for GLP-1 medications Prefer non-injectable treatment options Have experienced side effects with other therapies Are seeking medically supervised weight management support A licensed clinician will determine the most appropriate treatment approach based on medical history, current conditions, and overall health goals